lenabasum

Lenabasum is a synthetic oral small molecule and selective agonist of the cannabinoid receptor type 2 (CB2). It was developed as a non-immunosuppressive treatment for inflammatory and fibrotic diseases such as systemic sclerosis (including diffuse cutaneous systemic sclerosis), dermatomyositis, and cystic fibrosis. Lenabasum acts by binding to CB2 receptors on activated immune cells and fibroblasts to resolve inflammation and limit fibrosis. Its mechanism involves activation of CB2 leading to production of specialized pro-resolving lipid mediators like lipoxin A4 and prostaglandin J2 via arachidonic acid metabolism pathways. This results in reduced expression of genes/proteins involved in inflammation/fibrosis without significant immunosuppression or psychoactivity. Lenabasum was granted orphan drug designation for dermatomyositis but its development has since been discontinued[3][5][6][8].

Brand names

Lenabasum

Other names

AnabasumResunab